Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Peter Volz

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Schizophrenia Research|February 21, 2002
Input dysfunction and beyond--an evaluation of CPT componentsEckart R Straube, Natascha Bischoff, Carola Nisch, et al.
International Journal of Psychiatry in Clinical Practice|April 6, 2023
Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of SilexanSiegfried Kasper, Anne Eckert, Hans-Jürgen Möller, et al.
International Journal of Psychiatry in Clinical Practice|June 23, 2022
Subthreshold depression - concept, operationalisation and epidemiological data. A scoping reviewHans-Peter Volz, Johanna Stirnweiß, Siegfried Kasper, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 24, 2009
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysisMichael Bauer, Puvan Tharmanathan, Hans-Peter Volz, et al.
Experimental Brain Research|January 10, 2003
Processing of temporal information and the basal ganglia: new evidence from fMRIIgor Nenadic, Christian Gaser, Hans-Peter Volz, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 9, 2022
Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisitedLucie Bartova, Markus Dold, Hans-Peter Volz, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 23, 2016
The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practiceHans-Jürgen Möller, Borwin Bandelow, Hans-Peter Volz, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|May 18, 2017
Silexan in anxiety disorders: Clinical data and pharmacological backgroundSiegfried Kasper, Walter E Müller, Hans-Peter Volz, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 30, 2023
Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trialsMarkus Dold, Lucie Bartova, Hans-Peter Volz, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|March 1, 2024
Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trialsMarkus Dold, Hans-Jürgen Möller, Hans-Peter Volz, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Schizophrenia Research|February 21, 2002
Input dysfunction and beyond--an evaluation of CPT componentsEckart R Straube, Natascha Bischoff, Carola Nisch, et al.
International Journal of Psychiatry in Clinical Practice|April 6, 2023
Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of SilexanSiegfried Kasper, Anne Eckert, Hans-Jürgen Möller, et al.
International Journal of Psychiatry in Clinical Practice|June 23, 2022
Subthreshold depression - concept, operationalisation and epidemiological data. A scoping reviewHans-Peter Volz, Johanna Stirnweiß, Siegfried Kasper, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 24, 2009
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysisMichael Bauer, Puvan Tharmanathan, Hans-Peter Volz, et al.
Experimental Brain Research|January 10, 2003
Processing of temporal information and the basal ganglia: new evidence from fMRIIgor Nenadic, Christian Gaser, Hans-Peter Volz, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 9, 2022
Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisitedLucie Bartova, Markus Dold, Hans-Peter Volz, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 23, 2016
The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practiceHans-Jürgen Möller, Borwin Bandelow, Hans-Peter Volz, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|May 18, 2017
Silexan in anxiety disorders: Clinical data and pharmacological backgroundSiegfried Kasper, Walter E Müller, Hans-Peter Volz, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 30, 2023
Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trialsMarkus Dold, Lucie Bartova, Hans-Peter Volz, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|March 1, 2024
Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trialsMarkus Dold, Hans-Jürgen Möller, Hans-Peter Volz, et al.
Pageof 5